Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

被引：0
|
作者：
Dhanashree Ratra
Krishnakanta Roy
Sneha Giridhar
Sushant Madaan
机构：
[1] Medical Research Foundation,Department of Vitreoretinal Diseases
[2] Sankara Nethralaya,undefined
来源：
Ophthalmology and Therapy | 2022年 / 11卷
关键词：
Anti VEGF; Biosimilar; Comparison with bevacizumab; DME; nAMD; Ranibizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：135 / 149
页数：14
相关论文
共 50 条
  • [21] Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
    Sangroongruangsri, Sermsiri
    Chaikledkaew, Usa
    Kumluang, Suthasinee
    Wu, Olivia
    Geue, Claudia
    Ratanapakorn, Tanapat
    Leelahavarong, Pattara
    Ingsrisawang, Lily
    Ruamviboonsuk, Paisan
    Taweebanjongsin, Wongsiri
    Choovuthayakorn, Janejit
    Singalavanija, Apichart
    Hanutsaha, Prut
    Kulvichit, Kittisak
    Ratanapojnard, Thitiporn
    Wongsawad, Warapat
    Teerawattananon, Yot
    CLINICAL DRUG INVESTIGATION, 2018, 38 (09) : 853 - 865
  • [22] Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study
    Puren Isik
    Selcuk Sizmaz
    Ebru Esen
    Anıl Uysal
    Nihal Demircan
    International Ophthalmology, 2023, 43 : 4171 - 4180
  • [23] Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study
    Isik, Puren
    Sizmaz, Selcuk
    Esen, Ebru
    Uysal, Anil
    Demircan, Nihal
    INTERNATIONAL OPHTHALMOLOGY, 2023, 43 (11) : 4171 - 4180
  • [24] Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    V Chong
    Eye, 2016, 30 : 270 - 286
  • [25] Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    Chong, V.
    EYE, 2016, 30 (02) : 270 - 286
  • [26] Real-world outcomes of Ranibizumab treatment for Diabetic Macular Oedema
    Patrao, Namritha Valerie
    Antao, Sheelah
    Sim, Dawn A.
    Sivaprasad, Sobha
    Andrews, Richard
    Hamilton, Robin
    Egan, Catherine A.
    Tufail, Adnan
    Hykin, Philip G.
    Rajendram, Ranjan
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [27] Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
    Sermsiri Sangroongruangsri
    Usa Chaikledkaew
    Suthasinee Kumluang
    Olivia Wu
    Claudia Geue
    Tanapat Ratanapakorn
    Pattara Leelahavarong
    Lily Ingsrisawang
    Paisan Ruamviboonsuk
    Wongsiri Taweebanjongsin
    Janejit Choovuthayakorn
    Apichart Singalavanija
    Prut Hanutsaha
    Kittisak Kulvichit
    Thitiporn Ratanapojnard
    Warapat Wongsawad
    Yot Teerawattananon
    Clinical Drug Investigation, 2019, 39 : 115 - 115
  • [28] Comparison of anti-angiogenic effect in vitro between ranibizumab and bevacizumab
    Souto, Alexandre Cupello
    Maricato, Juliana Terzi
    Andrade Denapoli, Priscila Martins
    Ferraz Sallum, Juliana Maria
    Han, Sang Won
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2011, 74 (05) : 338 - 342
  • [29] Ranibizumab Pre-Filled Syringe Versus Ranibizumab Vial: Syringe Preparation Time in Real-World Clinical Practice
    Souied, Eric
    Nghiem-Buffet, Sylvia
    Leteneux, Claudia
    Bayer, Sascha
    Derveloy, Audrey
    Sagkriotis, Alexandros
    Becker, Guido
    Cohen, Salomon-Yves
    OPHTHALMOLOGICA, 2014, 232 : 70 - 70
  • [30] Erratum: Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    V Chong
    Eye, 2016, 30 : 1526 - 1526
12345